Sengupta N, et al. - From January 1, 2010, through December 31, 2014, a retrospective analysis of medical claims data from the Truven Health Marketscan Commercial Claims and Encounters Database was conducted to ascertain the frequency at which patients resume direct oral anticoagulants (DOAC) therapy following hospitalization for gastrointestinal bleeding (GIB) in a real-world setting, and the risks and benefits. Researchers reported that older patients who require blood and intensive care were less likely to restart treatment with DOACs after GIB in a retrospective analysis of medical claims data from adults treated with DOACs and hospitalized for GIB. Findings revealed that resuming DOAC therapy was not linked with thromboembolism within 90 days or recurrence of GIB. The data presented in this work showed a history of venous thromboembolism and thienopyridine use were correlated with risk of subsequent thromboembolism and GIB respectively.